Dr. Shin Kaneko, Director of Thyas and Professor at the Center for iPS Cell Research and Application, Kyoto University (CiRA), and his colleagues reports how gene editing iPS cells can lead to universal cancer immunotherapy that does not depend on the patient’s cells. The research finding was published in Nature Biomedical Engineering on May 18, 2021 (JST).

Click here for more details.